BridgeBio Pharma, Inc.

NasdaqGS:BBIO 株式レポート

時価総額：US$14.2b

BridgeBio Pharma 過去の業績

過去 基準チェック /06

BridgeBio Pharmaの収益は年間平均-7.8%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間34.1% 52.6%割合で 増加しています。

主要情報

-7.81%

収益成長率

0.74%

EPS成長率

Biotechs 業界の成長17.04%
収益成長率52.64%
株主資本利益率n/a
ネット・マージン-97.03%
前回の決算情報30 Jun 2026

最近の業績更新

Recent updates

Seeking Alpha • Sep 10

BridgeBio Pharma: Attruby Peak Sales Set To Rise

Summary BridgeBio Pharma has delivered multiple clinical and commercial successes, yet shares have repeatedly sold off after positive catalysts. Infigratinib's dwarfism trial outperformed the market leader, and Attruby continues to beat sales estimates, with management now guiding higher peak sales. Recent competitor setbacks and new data on Attruby's kidney benefits and hospital day reduction further strengthen BBIO's commercial outlook. I maintain a valuation of at least $100 per share today, with a long-term target of $300+, reflecting robust pipeline execution and rising revenue estimates. Read the full article on Seeking Alpha
ナラティブ更新 • Aug 26

BBIO: ATTR Cardiomyopathy Launch And Three Priority Reviews Will Reprice Shares

Analysts raised the BridgeBio Pharma fair value estimate from $135.94 to $139.85. This reflects updated views on Attruby revenue trends, pipeline progress, and revised P/E assumptions after a series of mixed but generally higher Street price targets through 2026.
分析記事 • Aug 13

Analysts Have Made A Financial Statement On BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Second-Quarter Report

Investors in BridgeBio Pharma, Inc. ( NASDAQ:BBIO ) had a good week, as its shares rose 2.3% to close at US$83.84...
ナラティブ更新 • Aug 12

BBIO: Multiple Priority Reviews And Rare Disease Launches Will Drive Post 2026 Upside

BridgeBio Pharma's updated analyst price target has nudged higher to about $108, with analysts pointing to continued progress for Attruby, multiple NDAs now under regulatory review, and an active rare disease pipeline as key drivers for the refined outlook. Analyst Commentary Recent Street research on BridgeBio Pharma highlights a mix of confidence in the company’s rare disease portfolio and some caution around competitive and payer related risks.
ナラティブ更新 • Jul 25

BBIO: Rare Disease Launch Wave And Priority Reviews Will Drive Post 2026 Upside

BridgeBio Pharma's fair value estimate has been revised slightly higher to $105.26 per share from $102.71, as analysts refresh models around updated price targets and pipeline expectations, particularly for Attruby, acoramidis and BBP-418. Analyst Commentary Recent research updates on BridgeBio Pharma reflect a mix of optimism and caution, with analysts recalibrating price targets as Attruby, acoramidis, BBP-418 and infigratinib progress through launch and regulatory milestones.
新しいナラティブ • Jul 19

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

The "BridgeBio Commercial Bonanza" is priced for perfection, treating the upcoming Acoramidis launch as an automatic cash cow while ignoring a brutal multi-front commercial dogfight. Here is why the market is mispricing the structural hurdles for BBIO: 1.
ナラティブ更新 • Jul 11

BBIO: Cardiomyopathy Launch And Rare Disease Filings Will Shape Next Phase

The analyst fair value estimate for BridgeBio Pharma has been raised from $76.00 to $80.00, reflecting updated Street price targets around $96 to $104 and analyst views that recent regulatory progress and ongoing launch execution support slightly higher projected growth, margins, and future P/E. Analyst Commentary Recent research on BridgeBio Pharma shows a mix of optimism around its rare disease portfolio and a more cautious stance from some bearish analysts who are focused on execution and valuation risks.
ナラティブ更新 • Jun 22

BBIO: ATTR Cardiomyopathy Rollout And Rare Disease NDA Milestones Will Reprice Shares

BridgeBio Pharma's updated analyst price target framework reflects a modestly higher fair value estimate of about $136, as analysts factor in mixed Street revisions that incorporate recent Q1 model updates, new coverage tied to Attruby and the rare disease pipeline, and differing views on payer risks and the recent regulatory milestones. Analyst Commentary Street commentary on BridgeBio Pharma currently reflects a mix of enthusiasm around Attruby, the rare disease portfolio, and key regulatory updates, offset by caution around payer dynamics and how these factors could influence valuation over time.
ナラティブ更新 • Jun 05

BBIO: Priority Review Rare Disease Pipeline Will Drive Post 2026 Upside

Analysts raised their blended fair value estimate for BridgeBio Pharma by about $1.82 to roughly $102.71, citing fresh price targets around $98 to $104, growing confidence in the Attruby launch, the broader rare disease pipeline, and added visibility from BBP-418's FDA Priority Review. Analyst Commentary Street research on BridgeBio Pharma is mixed, with several firms adjusting price targets and ratings around the Attruby launch, pipeline milestones, and regulatory updates such as the Priority Review for BBP-418.
ナラティブ更新 • May 20

BBIO: Cardiomyopathy Launch And Late Stage Filings Will Drive Next Phase

BridgeBio Pharma's fair value estimate has been trimmed by $4 to $76 as analysts balance a higher discount rate and more measured revenue growth against ongoing support for Attruby and the broader pipeline, as reflected in recent price target updates across the Street. Analyst Commentary Street research on BridgeBio continues to cluster around Attruby execution, valuation upside tied to pipeline milestones, and the impact of tafamidis settlement dynamics.
ナラティブ更新 • May 01

BBIO: Attruby Launch And Achondroplasia Data Will Support Post 2026 Upside

Analysts have inched their average price target for BridgeBio higher, with fair value estimates moving from about $100.61 to $100.89 as they factor in updated views on Attruby traction, achondroplasia data, and the potential impact of recent settlement headlines with large pharma peers. Analyst Commentary Street research on BridgeBio has been active, with price targets and fair value estimates moving as analysts update their views on Attruby uptake, achondroplasia data, and the implications of recent settlement headlines with large pharmaceutical peers.
ナラティブ更新 • Apr 17

BBIO: Attruby Momentum And Late Stage Pipeline Will Support Post 2026 Confidence

Analysts have nudged their fair value target for BridgeBio Pharma higher, from $100.05 to $100.61, citing stronger assumptions around Attruby traction, a wider late stage pipeline, and updated P/E expectations reflected in recent price target hikes across several firms. Analyst Commentary Street research around BridgeBio has been active, with several firms updating models after Q4 Attruby data, infigratinib readouts and fresh coverage initiations.
ナラティブ更新 • Apr 03

BBIO: ATTR-CM Franchise And Achondroplasia Program Are Expected To Reprice Shares

Analysts slightly raised their average price target on BridgeBio Pharma to $132.57 per share, citing updated models that factor in recent Attruby sales trends, positive infigratinib achondroplasia data, and the company’s progress toward becoming a multi-product commercial business. Analyst Commentary Bullish analysts have been steadily lifting their price targets on BridgeBio Pharma in recent months, reflecting updated views on valuation that incorporate Attruby sales, late stage pipeline progress, and the company’s push toward a broader commercial footprint.
ナラティブ更新 • Mar 20

BBIO: Late-Stage Genetic Programs And ATTR-CM Franchise Are Expected To Reprice Shares

The updated analyst price target for BridgeBio Pharma moves to $132.57, reflecting analysts' focus on stronger fair value assumptions, a slightly lower discount rate, and higher projected profit margins supported by recent research pointing to Attruby's momentum and late stage pipeline progress. Analyst Commentary Recent Street research points to a cluster of bullish analysts revisiting their models on BridgeBio Pharma, with several lifting fair value estimates and highlighting execution around Attruby and the late stage pipeline.
ナラティブ更新 • Mar 05

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Beyond 2026

The analyst fair value estimate for BridgeBio Pharma has increased from $89.79 to $100.05, reflecting a series of upward revisions to Street price targets as analysts factor in stronger Attruby sales trends and progress across the broader late-stage pipeline. Analyst Commentary Recent research updates cluster around two main themes for BridgeBio Pharma: valuation support from Attruby, and expectations for the broader late stage pipeline.
ナラティブ更新 • Feb 19

BBIO: Phase 3 Achondroplasia Data And Broad Pipeline Will Shape Next Phase

The analyst price target for BridgeBio Pharma has been reset from $41 to $80, with analysts citing recent price target increases across the Street and positive Phase 3 PROPEL 3 achondroplasia data as key supports for the higher fair value view. Analyst Commentary Recent Street research has pointed to higher price targets for BridgeBio Pharma following the Phase 3 PROPEL 3 readout and updated views on the company’s late stage pipeline.
ナラティブ更新 • Feb 05

BBIO: Late-Stage Genetic Programs Are Expected To Support Bullish Repricing

Analysts have lifted their price targets on BridgeBio Pharma, supporting a higher implied fair value of about $128 per share as they factor in updated models, a strengthened view of the company’s late stage pipeline and expectations for its genetic disease portfolio. Analyst Commentary Bullish analysts are leaning into a higher fair value framework for BridgeBio, updating models around the genetic disease portfolio and later stage programs.
ナラティブ更新 • Jan 22

BBIO: Late Stage Genetic Pipeline Progress Will Support Confidence Into 2026

Analysts have lifted their fair value estimate for BridgeBio Pharma to about $89.79 from roughly $84.65, citing higher modeled revenue growth and profit margins, along with updated expectations for the late stage pipeline and therapies such as Attruby, encaleret and BBP-418. Analyst Commentary Recent research updates highlight a generally constructive stance on BridgeBio Pharma, with multiple firms revising price targets and pointing to the late stage pipeline and commercial traction of key assets as central to their views.
ナラティブ更新 • Jan 07

BBIO: Late-Stage Genetic Programs Are Expected To Drive Bullish Repricing

Analysts have trimmed their fair value estimate for BridgeBio Pharma slightly to about $108.70 per share from $109.61. This reflects updated views on higher projected revenue growth, a wider profit margin profile, and a lower assumed future P/E multiple informed by recent positive readouts and pipeline driven price target increases across the Street.
ナラティブ更新 • Dec 24

BBIO: Late-Stage Pipeline Progress Will Drive Bullish Repricing Ahead

BridgeBio Pharma's analyst price target has been raised meaningfully, with fair value estimates climbing from approximately $88 to $110 as analysts factor in stronger visibility on late stage programs like Attruby, infigratinib, encaleret, and BBP-418. These programs collectively de risk the pipeline and support higher long term profitability.
ナラティブ更新 • Dec 10

BBIO: Late Stage Pipeline Progress Will Drive Confidence Into 2026 And Beyond

Analysts nudged their average price target for BridgeBio Pharma up by about $1 to roughly $84.65 per share, citing stronger than expected Attruby revenue traction, rising conviction in BBP-418 and encaleret Phase 3 success, and greater visibility on multiple late stage catalysts into 2026. Analyst Commentary Bullish analysts are largely aligned on a constructive outlook for BridgeBio, emphasizing upside to current revenue forecasts, increasing confidence in late stage programs, and a clearer path to market for several key assets.
ナラティブ更新 • Nov 26

BBIO: Positive Regulatory Momentum Will Drive Confidence Ahead Of 2026 Approvals

BridgeBio Pharma's analyst price target has been raised slightly, increasing from $83.11 to $83.65. Analysts cite positive clinical updates, higher probability of regulatory approvals, and stronger than expected revenue performance as key drivers for the upward revision.
ナラティブ更新 • Nov 10

BBIO: Positive Late-Stage Data Will Drive Confidence Ahead Of 2026 Regulatory Decisions

BridgeBio Pharma's analyst price target has been raised significantly, from approximately $66 to over $83. Analysts cite stronger-than-expected revenue, promising pipeline data, and increased confidence in future product approvals as key drivers for the upward revision.
ナラティブ更新 • Oct 27

Pipeline Opportunities And Clinical Catalysts Will Drive Long-Term Biotech Expansion

BridgeBio Pharma's analyst price target has been revised upward, with the average fair value increasing modestly from $66.32 to $66.47. Analysts highlight strong early commercial momentum, underappreciated pipeline opportunities, and rising revenue estimates for key assets.
ナラティブ更新 • Oct 13

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Analysts have raised their price targets on BridgeBio Pharma by as much as $10 to $82 per share. They cite better-than-expected drug uptake, upcoming clinical milestones, and upgraded sales projections as justification for their increased optimism.
ナラティブ更新 • Sep 29

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

BridgeBio Pharma’s consensus price target was revised upward, driven by stronger-than-expected commercial uptake of Acoramidis (Attruby), upwardly revised peak sales estimates for key assets, and de-risked late-stage pipeline catalysts, resulting in a new price target of $66.32 from $65.10. Analyst Commentary Bullish analysts cite strong commercial momentum and better-than-expected uptake of Acoramidis (Attruby), particularly in transthyretin amyloid cardiomyopathy (ATTR-CM), as driving upward revisions to price targets.
ナラティブ更新 • Sep 14

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

BridgeBio Pharma’s consensus price target has been raised to $65.10, driven by increasing analyst confidence in its pipeline progress—particularly for ADH1 and BBP-418, ongoing strong sales momentum for Attruby in ATTR-CM, and multiple upcoming catalysts—reflecting a notably improved valuation outlook. Analyst Commentary Bullish analysts are confident in Phase 3 data readouts for pipeline assets, particularly autosomal dominant hypocalcemia type 1 (ADH1) and limb-girdle muscular dystrophy type 2I/R9 (BBP-418), viewing them as underappreciated and meaningful opportunities likely to expand BridgeBio’s addressable market.
ナラティブ更新 • Aug 30

Precision Medicine And Pipeline Advancements Will Expand Biotech Horizons

Analysts raised BridgeBio Pharma's price target from $62.43 to $63.10, citing stronger-than-expected uptake of Acoramidis (Attruby), major upcoming Phase 3 catalysts, and increased confidence in pipeline diversification and commercial momentum. Analyst Commentary Bullish analysts highlight stronger-than-expected commercial uptake for Acoramidis (Attruby), surpassing initial projections.

収支内訳

BridgeBio Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:BBIO 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 26713-692646505
31 Mar 26580-722589467
31 Dec 25502-725531452
30 Sep 25354-797451466
30 Jun 25236-776399473
31 Mar 25127-668329477
31 Dec 24222-536289506
30 Sep 24218-439242506
30 Jun 24219-454209511
31 Mar 24219-538185504
31 Dec 239-643151456
30 Sep 239-613135416
30 Jun 236-573130384
31 Mar 2378-425131385
31 Dec 2278-481143399
30 Sep 2289-491166431
30 Jun 2291-509181443
31 Mar 2271-596191436
31 Dec 2170-563189451
30 Sep 2157-535172419
30 Jun 2163-495162407
31 Mar 219-520154391
31 Dec 208-449146337
30 Sep 2022-402143304
30 Jun 2041-346131268
31 Mar 2041-291110233
31 Dec 1941-26194210
30 Sep 1927-22674204
30 Jun 190-19761180
31 Mar 190-15554151
31 Dec 180-13144140

質の高い収益: BBIOは現在利益が出ていません。

利益率の向上: BBIOは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: BBIOは利益が出ておらず、過去 5 年間で損失は年間7.8%の割合で増加しています。

成長の加速: BBIOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BBIOは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。

株主資本利益率

高いROE: BBIOの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/14 05:27
終値2026/09/14 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

BridgeBio Pharma, Inc. 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37

アナリスト機関
Eliana MerleBarclays
"Eliana MerleBarclays
Jason ZemanskyBofA Global Research